期刊文献+

Effect of dobutamine combined with meropenem on serum BNP, IGF-1, IGFBP-3, TNF-a, IL-6 and hs-CRP in children with congenital heart disease and pneumonia 被引量:1

下载PDF
导出
摘要 Objective:To study the effect of dobutamine combined with meropenem on serum BNP, IGF-1, IGFBP-3, TNF-a, IL-6 and hs-CRP in children with congenital heart disease and pneumonia.Methods:A total of 70 children with congenital heart disease and pneumonia in our hospital from June 2014 to Octomber 2016 were enrolled in this study. The subjects were divided into the control group (n=35) and the treatment group (n=35) randomly. The control group was treated with dobutamine, the treatment group were treated with dobutamine combined with meropenem. The two groups were treated for 10 days. The serum BNP, IGF-1, IGFBP-3, TNF-a, IL-6 and hs-CRP levels of the two groups before and after treatment were compared.Results: There were no significantly differences of the serum BNP, IGF-1, IGFBP-3, TNF-a, IL-6 and hs-CRP levels of the two groups before treatment. The serum BNP, TNF-a, IL-6 and hs-CRP levels of the two groups after treatment were significantly lower than before treatment, the serum IGF-1 and IGFBP-3 levels of the two groups after treatment were significantly higher than before treatment, and that of the treatment group were significantly better than the control group.Conclusion:Dobutamine combined with meropenem can significantly reduce the serum BNP, TNF-a, IL-6 and hs-CRP levels, improve serum IGF-1 and IGFBP-3 levels of children with congenital heart disease and pneumonia, and it was worthy clinical application.
出处 《Journal of Hainan Medical University》 2017年第12期83-86,共4页 海南医学院学报(英文版)
  • 相关文献

参考文献7

二级参考文献53

  • 1白凯.先天性心脏病相关肺动脉高压[J].中华临床医师杂志(电子版),2010,4(6):711-713. 被引量:15
  • 2谢育梅,李渝芬,徐衍梅,潘微,王树水.前列地尔对先天性心脏病合并重度肺动脉高压的治疗作用[J].临床儿科杂志,2005,23(3):149-151. 被引量:11
  • 3郭军,盖鲁粤,杨庭树,刘宏斌,王禹,陈练.危重急性心肌梗死患者住院死亡的危险因素分析[J].内科急危重症杂志,2007,13(4):125-127. 被引量:10
  • 4Okyay K, Cemri M, Boyac B, et al. Use of long-term combinedtherapy with inhaled iloprost and oral sildenafil in an adult patientwith eisenmenger syndrome [J]. Cardiol Rev, 2005,13(6):312-314.
  • 5Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil inpatients with Eisenmenger syndrome versus idiopathic pulmonaryarterial hypertension [J]. Int J Cardiol, 2007,120(3) : 301-305.
  • 6Beghetti M, Gali N. Eisenmenger syndrome a clinical perspectivein a new therapeutic era of pulmonary arterial hypertension [ J]. JAm Coll Cardiol, 2009, 53(9) ; 733-740.
  • 7Jacobs E.Mycoplasma pneumoniae:now in the focus of clini-cians and epidemiologists[J].Euro Surveill,2012,17(6).
  • 8Medina JL,Coalson JJ,Brooks EG et al.Mycoplasma pneu-moniae CARDS toxin induces pulmonary eosinophilic and lym-phocytic inflammation[J].Am J Respir Cell Mol Biol,2012 Jan26.
  • 9Arae K,Hirata M,Kurata S et al.Mycoplasma pneumoniae induces interleukin-8production via the epidermal growth factor receptor pathway[J].Microbiol Immunol,2011,55(10):748.
  • 10Wallis RS.Biologics and infections:lessons from tumor necro-sis factor blocking agents[J].Infect Dis Clin North Am,2011,25(4):895.

共引文献67

同被引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部